NASDAQ · Biotechnology · USD
Genelux Corporation (GNLX) Stock Analysis
Genelux Corporation (GNLX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
GNLX Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.53
- Previous Close
- $2.50
- Day's Range
- 2.02–2.57
- 52-Week Range
- 2.02–8.54
- Volume
- 832.61K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.58
Valuation
- Market Cap
- $93.66M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.86
Financials (FY)
- Revenue (FY)
- $8.00K+0.00%
- Net Income (FY)
- −$32.15M
- Shares Outstanding
- 45.25M
- 1-Year Return
- −69.20%
Dividend and dates
- Avg Volume
- 293.09K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, GNLX closed at $2.07, −69.20% over 1 year.
Genelux Corporation (GNLX) has a market capitalization of $93.66M.
In fiscal 2025, GNLX reported revenue of $8.00K.
GNLX Stock Return by Calendar Year
Genelux Corporation (GNLX) return since Jan 2023: what $10,000 became
- 1 year
- $10,000 $3,080
- −69.20%
- 3 years
- $10,000 $1,028
- −89.72%
- Since Jan 2023
- $10,000 $3,366
- −66.34%
If you had invested $10,000 in Genelux Corporation (GNLX) at the close on January 26, 2023, the earliest close on record here, it would have been worth $3,366 at the close on October 21, 2026: −66.34% in total, −25.29% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −52.52% |
| 2025 | +84.75% |
| 2024 | −83.15% |
| 2023 | +127.80% |
As of October 21, 2026.
GNLX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $8.00K | −$32.15M | −401,812.5% |
| 2024 | $8.00K | −$29.87M | −373,362.5% |
| 2023 | $170.00K | −$28.30M | −16,645.3% |
| 2022 | $11.07M | −$5.21M | −47.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $8.00K | — | −$33.21M | −$32.15M | −401,812.5% |
| 2024 | $8.00K | — | −$31.70M | −$29.87M | −373,362.5% |
| 2023 | $170.00K | — | −$24.17M | −$28.30M | −16,645.3% |
| 2022 | $11.07M | — | −$3.01M | −$5.21M | −47.0% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
YahooGenelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B